Floatz logo

Leucine

Corticobasal Degeneration (CBD)

Washington University School of MedicineSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Corticobasal Degeneration (CBD) cohort.

Asset / SponsorPhaseRating
LITHIUM, ELEMENTAL
Westat
Phase 1/2CCC
Davunetide
University of California, San Francisco
Phase 1CC
GOSURANEMAB
University of California, San Francisco
Phase 1CC
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
D
ER-176
Mayo Clinic
D
FLORTAUCIPIR
Mayo Clinic
D

Same molecule, other indications

Leucine is also rated in:

obesity disorderDormant
CC
Indicative ·
46 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative ·
30 / 100
View asset →
hyperglycemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →